Skip to main content
Clinical Trials/NCT02525237
NCT02525237UnknownPhase 2

Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Qingdao Municipal Hospital0 sites30 target enrollmentStarted: August 2015Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 2
Sponsor
Enrollment
30
Primary Endpoint
Progression Free Survival

Study Overview

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of Apatinib combined with S-1 as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adult patients, aged ≥18 years;
  • Histologically confirmed adenocarcinoma of the stomach with inoperable locally advanced or recurrent and/or metastatic disease;
  • Measurable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1);
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3;
  • No previous chemotherapy for advanced/metastatic disease 1) Prior adjuvant/neoadjuvant therapy is allowed if at least 6 months has elapsed between completion of adjuvant/neoadjuvant therapy and enrolment into the study); 2) No previous targeted therapy; 3) For patients who can't tolerate first-line chemotherapy or refuse to accept chemotherapy, if they request to participate in this study, may receive apatinib monotherapy after consultation with the principal investigator in consideration of ethics.
  • Hematological, Biochemical and Organ Functions: HB ≥ 80 g/L, ANC ≥ 1.5×109/L, PLT ≥ 80×109/L, BIL < 1.5×ULN, ALT or AST < 2.5×ULN (or < 5×ULN in patients with liver metastases), Serum Cr ≤ 1×ULN, Cr clearance ≥ 50 mL/min;
  • Life expectancy of more than 3 months;
  • Duration from operation is more than 4 weeks;
  • For women of child-bearing age, the pregnancy test results (serum or urine) within 7 days before enrolment must be negative. They will take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men (previous surgical sterilization accepted), will take appropriate methods for contraception during the study until the 8th week post the last administration of study drug.
  • Signed informed consent.

Exclusion Criteria

  • Patients with poor-controlled arterial hypertension (systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mm Hg) despite standard medical management; Coronary heart disease, arrhythmia (including QT interval prolongation, for man > 450 ms, for woman > 470 ms), and cardiac dysfunction greater than Class II;
  • Factors affecting the oral medication, such as inability to swallow, chronic diarrhea and intestinal obstruction;
  • Patients with a clear tendency of gastrointestinal bleeding;
  • Abnormal coagulation function (INR > 1.5×ULN, APTT > 1.5×ULN), with tendency of bleed;
  • Pregnant or lactating women;
  • Other conditions regimented at investigators' discretion.

Arms & Interventions

Apatinib plus S-1

Experimental

Apatinib (500 mg qd p.o.) concomitantly with S-1 (40 mg/m2 qd days 1-14 q3w p.o.)

Intervention: Apatinib (Drug)

Apatinib plus S-1

Experimental

Apatinib (500 mg qd p.o.) concomitantly with S-1 (40 mg/m2 qd days 1-14 q3w p.o.)

Intervention: S-1 (Drug)

Outcomes

Primary Outcomes

Progression Free Survival

Time Frame: Event driven, an expected average of 8 months

Safety will be assessed by incidence of adverse events

Time Frame: An expected average of 8 months

Secondary Outcomes

  • Objective response rate (ORR)(An expected average of 8 months)
  • Disease control rate (DCR)(An expected average of 8 months)
  • Overall survival (OS)(Event driven, an expected average of 24 months)
  • Quality of life (QoL)(An expected average of 24 months)

Investigators

Sponsor
Qingdao Municipal Hospital
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Xiaochun Zhang

Chairman

Qingdao Municipal Hospital

Similar Trials

Apatinib in Combination With S-1 as... | Clinical Trial